Literature DB >> 25853954

Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation.

Yingying Zhao1, Chaonan Sun1, Feng Shi1, Caleb Kesse Firempong1, Jiangnan Yu1, Ximing Xu1, Weiming Zhang2.   

Abstract

CONTEXT: Capsaicin (CAP) is an effective drug in the treatment of pain and cancer. However, its practical administration has been limited due to poor aqueous solubility and bioavailability, as well as strong gastrointestinal irritation.
OBJECTIVE: The objective of this study is to improve the solubility and oral bioavailability of CAP by reducing irritation via hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex formulation, in vitro and in vivo analysis.
MATERIALS AND METHODS: The complex (CAP-HP-β-CD) was developed via the magnetic stirring method and characterized using ultraviolet (UV) absorption spectrometry, infrared radiation (IR) spectroscopy, and differential scanning calorimetry (DSC). Rats were treated with CAP (90 mg × kg(-1)) or CAP-HP-β-CD (corresponding to 90 mg × kg(-1) CAP) by gavage, and all the plasma samples were analyzed with high performance liquid chromatography (HPLC).
RESULTS: The results of UV, IR, and DSC showed that an acceptable CAP-HP-β-CD (encapsulation efficiency, 75.83%; drug loading, 7.44%) was formulated. In vitro release study of CAP-HP-β-CD revealed that the cumulative release of CAP from HP-β-CD encapsulation was obviously enhanced (above 80% increases). Similarly, the in vivo pharmacokinetics parameters also increased, Cmax (from 737.94 to 1117.57 ng × mL(-1)), AUC0- (from 5285.9 to 7409.8 ng × h × mL(-1)) or relative bioavailability (139.38%). The gastric irritation bioassay further showed that the CAP-HP-β-CD was far better than free CAP. DISCUSSION AND
CONCLUSION: CAP exhibited significant aqueous solubility and oral bioavailability, as well as minimal irritation effect after forming inclusion complex with HP-β-CD. Therefore, these findings could provide an equally important alternative option for the clinical use of CAP.

Entities:  

Keywords:  HP-β-CD; in vitro release; irritation; oral bioavailability

Mesh:

Substances:

Year:  2015        PMID: 25853954     DOI: 10.3109/13880209.2015.1021816

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  6 in total

1.  Preparation and Evaluation of PLGA-Coated Capsaicin Magnetic Nanoparticles.

Authors:  Mrudhula Baskaran; Padmamalini Baskaran; Navamoney Arulsamy; Baskaran Thyagarajan
Journal:  Pharm Res       Date:  2017-03-21       Impact factor: 4.200

2.  One-Step Encapsulation of Capsaicin into Chitosan-Oleic Acid Complex Particles: Evaluation of Encapsulation Ability and Stability.

Authors:  Takashi Kuroiwa; Yoshiki Higuchi
Journal:  Polymers (Basel)       Date:  2022-05-26       Impact factor: 4.967

3.  Glucose- and temperature-sensitive nanoparticles for insulin delivery.

Authors:  Jun-Zi Wu; Gareth R Williams; He-Yu Li; Dongxiu Wang; Huanling Wu; Shu-De Li; Li-Min Zhu
Journal:  Int J Nanomedicine       Date:  2017-05-29

4.  Enhanced Solubility and Anticancer Potential of Mansonone G By β-Cyclodextrin-Based Host-Guest Complexation: A Computational and Experimental Study.

Authors:  Panupong Mahalapbutr; Piyanuch Wonganan; Thanapon Charoenwongpaiboon; Manchumas Prousoontorn; Warinthorn Chavasiri; Thanyada Rungrotmongkol
Journal:  Biomolecules       Date:  2019-09-27

5.  Period1 mediates rhythmic metabolism of toxins by interacting with CYP2E1.

Authors:  Wenhao Ge; Tao Wang; Yang Zhao; Yunxia Yang; Qi Sun; Xiao Yang; Yan Gao; Xi Xu; Jianfa Zhang
Journal:  Cell Death Dis       Date:  2021-01-12       Impact factor: 8.469

6.  Capsaicin-Cyclodextrin Complex Enhances Mepivacaine Targeting and Improves Local Anesthesia in Inflamed Tissues.

Authors:  Verônica Muniz Couto; Laura de Oliveira-Nascimento; Luiz Fernando Cabeça; Danilo Costa Geraldes; Juliana Souza Ribeiro Costa; Karin A Riske; Michelle Franz-Montan; Fabiano Yokaychiya; Margareth K K Dias Franco; Eneida de Paula
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.